白蛋白结合型紫杉醇治疗多线化疗失败的晚期难治性乳腺癌

Albumin-bound paclitaxel in the treatment of advanced refractory breast cancer after failed multiline chemotherapy

目的观察白蛋白结合型紫杉醇单药治疗多线化疗失败的晚期难治性乳腺癌的疗效和安全性。方法34例既往多线（≥3）化疗治疗失败的晚期难治性乳腺癌患者，接受白蛋白结合型紫杉醇化疗，观察治疗效果。结果34例患者中，完全缓解0例，部分缓解9例，稳定17例，进展8例，有效率26．5％，中位无疾病进展时间（PFS）3．8个月，中位生存期（OS）8．5个月。主要毒副反应为骨髓抑制，Ⅲ-Ⅳ度白细胞减少35．3％，其余多为Ⅰ-Ⅱ度毒副反应。结论白蛋白结合型紫杉醇单药治疗多线治疗失败的晚期难治性乳腺癌，仍有较好的疗效，毒性小，为有效的解救方案。

Objective To observe curative effect and safety by albumin-bound paclitaxel in monotherapy of advanced refractory breast cancer after failed multi-line chemotherapy. Methods Albumin- bound paclitaxel chemotherapy was given to 34 patients with advanced refractory breast cancer after failed multi- line （ ≥3） chemotherapy. Curative effect was observed. Results There were 0 case with complete remission, 9 cases with partial remission, 17 stable cases, g developed cases among 34 cases, with the effective rate as 26.5%. Median progression free survival （PFS） was 3.8 months, and median overall survival （OS） was 8.5 months. Main toxic and side reactions included myelosuppression, Ⅲ-Ⅳ degree leucopenia by 35.3%, and Ⅰ-Ⅱ degree toxic and side effects. Conclusion As an effective treatment method, implement of albumin-bound paclitaxel provides good effect and low toxicity in monotherapy of advanced refractory breast cancer after failed multi-line chemotherapy.